Navigation Links
Circulating tumor cells in blood can predict a patient's response to chemotherapy
Date:12/3/2013

Scientists from Granada have demonstrated, for the first time, that detecting circulating tumour cells (CTCs) in blood and studying the presence of certain genetic markers in them is a technique that allows specialists to predict, with great precision, the response that advanced-cancer patients will have to chemotherapy, as well as the associated secondary effects they may suffer. The key lies in identifying specific proteins in these cells, which make them particularly sensitive to specific drugs.

The scientists, from the Circulating Tumour Cells and Metastasis research group of GENYO (Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Govt.) have received an award at the 9th International Symposium on Minimal Residual Cancer, held recently in Paris, for their study into the use of CTCs and specific markers in these cells, as a clinical tool to determine the response to treatments administered to patients with advanced cancer of the colon.

The patients, studied in the Oncology Unit of the Clinical Hospital of Granada and the Hospital of Motril, underwent a standard treatment in this illness, which includes chemotherapy and a specific monoclonal antibody that reduces the vascularization of the tumour. The study was carried out in collaboration with the Roche Farma laboratory.

The importance of CTCs as the origin of metastasis, which, in turn, is the cause of more than 9 out of every 10 deaths from cancer, has been the subject of work by this group in GENYO for over four years, lead by the University of Granada professors, Jos Antonio Lorente, Mara Jos Serrano and Jos Luis Garca Puche.

GENYO co-operates actively with other Spanish hospitals such as Jan (Dr. Snchez Rovira's team), Crdoba (Dr. Aranda's team) or Almera - Torrecrdenas (with Dr. Juan Torres), as well as carrying out other particularly relevant collaborations with the Dexeus Institute or the Hospital del Mar in Barcelona, along with others in Granada (teams led by Drs. Expsito, Delgado, Czar and Cueto, among others).

Eight Studies

This test on CTCs is one of eight studies the Granada research group is currently carrying out on patients affected by various particularly relevant pathologies in oncology, such as breast cancer, lung cancer, peritoneal carcinomatosis or prostate cancer. These studies have been funded by the Andalusian Regional Government's Health Council, the University of Granada and the pharmaceutical sector.

Due to the importance of this research in applying anti-cancer treatments with greater precision and with fewer side-effects, as well as the importance of CTCs in diagnosing the illness, the work of this GENYO group has caught the attention of the pharmaceutical industry, which habitually collaborates in the carrying out of some of the studies, such as SANOFI, Pangaea, Janssen, Amgen, Ingeniatrix or Roche Farma.


'/>"/>

Contact: José Antonio Lorente
jlorente@ugr.es
34-958-715-500
University of Granada
Source:Eurekalert  

Related medicine news :

1. New research finds flu shot effective regardless of circulating flu strain
2. Sous Vide Circulating Bath Systems Enable Chefs to Achieve Perfect Results
3. Detecting circulating tumor cells
4. New technology allows scientists to capture and preserve cancer cells circulating in the bloodstream
5. Capturing circulating cancer cells could provide insights into how disease spreads
6. Blocking antioxidants in cancer cells reduces tumor growth in mice
7. Why tumors become resistant to chemotherapy?
8. New immunotherapy for malignant brain tumors
9. Study Funded by National Foundation for Cancer Research Reveals Imaging Studies May Predict Tumor Response to Anti-Angiogenic Drugs
10. American Brain Tumor Association-Funded Research Spurs Development of New Treatments
11. Study unveils SINEs potential of re-activating tumor fighting proteins within a cell
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Circulating tumor cells in blood can predict a patient's response to chemotherapy
(Date:7/20/2017)... ... ... A July 5th article on Reuters Health News discusses a ... body contouring procedure reported experiencing a better quality of life, compared to other patients. ... types of procedures, notes that this report jibes with what they regularly hear from ...
(Date:7/18/2017)... CA (PRWEB) , ... July 18, 2017 , ... CannaKids, ... scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place in ... be speaking on the therapeutic benefits of medical cannabis for both pediatric and adult ...
(Date:7/18/2017)... Indio, California (PRWEB) , ... July 18, 2017 ... ... providers working on a lien basis, partners with the best medical professionals who ... Liens pre-screens and pre-approves each medical professional in their network, ensuring that each ...
(Date:7/18/2017)... ... 19, 2017 , ... USHEALTH Group, Inc. has been announced ... prestigious CEO World Awards®. The coveted annual CEO World Awards program encompasses ... case studies, corporate social responsibility, and milestones from every major industry in the ...
(Date:7/17/2017)... ... ... McGraw Family Pledges $3 Million for New Learning Center at Norwalk Hospital, New ... NORWALK, Connecticut – July 17, 2017 – The McGraw family, founders of global multimedia ... up to $3 million in a challenge gift to establish the new McGraw Family ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
(Date:6/27/2017)... , June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... company specializing in the development of cannabinoid-based drugs, today ... Market Opening Bell in New York, NY ... of its initial public offering (IPO) of American Depository ... March 2017. Dr. Elran Haber, Ph.D., Chief ...
(Date:6/20/2017)... 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... Friday, July 28, 2017, beginning at 7:30 a.m. (CDT) / ... information: To participate in the conference call, dial (877) 304-8969 ... at least 10 minutes prior to the start to allow ... Webcast: A simultaneous webcast of ...
Breaking Medicine Technology: